AMGEN INC. $1,000,000,000 3.200% SENIOR NOTES DUE 2027 Underwriting AgreementUnderwriting Agreement • November 2nd, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 principal amount of its 3.200% Senior Notes due 2027 (the “Securities”) to be issued pursuant to the provisions of an Indenture dated as of May 22, 2014 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as Trustee (the “Trustee”). J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BNP Paribas Securities Corp. have agreed to act as representatives of the Underwriters (the “Representatives”).
